$IMUX on NASDAQ
March 07, 2024
Immunic to Participate in Investor and Scientific Conferences in March
February 29, 2024
Immunic Presents Data From Phase 2 CALLIPER and CALVID-1 Trials of Vidofludimus Calcium at the ACTRIMS Forum 2024
February 22, 2024
Immunic, Inc. Reports Year End 2023 Financial Results and Provides Corporate Update
February 15, 2024
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2023, and Provide Corporate Update
February 01, 2024
Immunic to Participate in Investor and Scientific Conferences in February
January 05, 2024
Immunic Highlights 2023 Accomplishments and Upcoming Milestones
January 05, 2024
Immunic, Inc. Announces Private Placement of up to $240 Million
November 21, 2023
Immunic Receives Notice of Allowance for United States Patent Protecting Vidofludimus Calcium's Dosing Regimens in Multiple Sclerosis
November 14, 2023
Immunic, Inc. Reports Third Quarter 2023 Financial Results and Provides Corporate Update
November 07, 2023
Immunic to Announce Financial Results for the Third Quarter Ended September 30, 2023, and Provide Corporate Update
October 26, 2023
Immunic to Participate in Scientific and Industry Conferences in November
October 16, 2023
Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
October 15, 2023
Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
October 11, 2023
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
October 09, 2023
Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
October 04, 2023
Immunic to Participate in Scientific Conferences in October
September 06, 2023
Immunic to Participate in Industry and Investor Conferences in September
August 17, 2023
Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
August 03, 2023
Immunic, Inc. Reports Second Quarter 2023 Financial Results and Provides Corporate Update
August 01, 2023
Immunic to Participate in Investor and Scientific Conferences in August
July 27, 2023
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2023, and Provide Corporate Update
June 29, 2023
Immunic to Participate in Scientific and Investor Conferences in July
May 30, 2023
Immunic to Participate in Scientific and Investor Conferences in June
May 17, 2023
Immunic Announces That Vidofludimus Calcium Acts as Potent Nurr1 Activator, Reinforcing Neuroprotective Potential in Multiple Sclerosis
May 11, 2023
Immunic, Inc. Reports First Quarter 2023 Financial Results and Provides Corporate Update
May 09, 2023
Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2023, and Provide Corporate Update
May 06, 2023
Immunic Presents Clinical and Preclinical Data for IMU-856 at Digestive Disease Week 2023, Including Its Molecular Mode of Action
May 04, 2023
Immunic Reports Positive Results From Phase 1b Clinical Trial of IMU-856 in Celiac Disease, Providing Clinical Proof-of-Concept for New Therapeutic Approach to Gastrointestinal Disorders
April 27, 2023
Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Richard Rudick, M.D.
April 26, 2023
Immunic to Participate in Investor and Scientific Conferences in May
April 05, 2023
Immunic Reports Positive Data from Maintenance Phase of Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Moderate-to-Severe Ulcerative Colitis
March 02, 2023
Immunic to Participate in Investor and Scientific Conferences in March
February 23, 2023
Immunic, Inc. Reports Year End 2022 Financial Results and Provides Corporate Update
February 22, 2023
Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at ACTRIMS Forum 2023
February 16, 2023
Immunic, Inc. to Announce Financial Results for the Year Ended December 31, 2022, and Provide Corporate Update
February 09, 2023
Immunic to Host Virtual Celiac Disease R&D Day to Highlight Current Pathways for Drug Development and Unmet Medical Need
January 25, 2023
Immunic to Participate in Scientific and Investor Conferences in February
November 17, 2022
Immunic Reports New Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis Supporting the Drug's Neuroprotective Potential
November 10, 2022
Immunic to Participate in Investor and Scientific Conferences in November and December
November 03, 2022
Immunic, Inc. Reports Third Quarter 2022 Financial Results and Provides Corporate Update
October 27, 2022
Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2022, and Provide Corporate Update
October 20, 2022
Immunic Reports Pre-Planned Phase 1b Interim Analysis of IMU-935 in Psoriasis Patients Confounded by High Placebo Rate
October 10, 2022
Immunic, Inc. Announces $60.0 Million Oversubscribed Private Placement Equity Financing
October 04, 2022
Immunic to Participate in Scientific and Industry Conferences in October
September 20, 2022
Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human Subjects
September 01, 2022
Immunic, Inc. to Participate in Investor Conferences in September
August 16, 2022
Immunic Receives Notice of Allowance for Composition-of-Matter Patent in the United States for IMU-856, a Small Molecule Modulator Targeting Restoration of Intestinal Barrier Function and Regeneration of Bowel Epithelium
August 04, 2022
Immunic, Inc. Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 02, 2022
Immunic, Inc. to Participate in the 2022 Wedbush PacGrow Virtual Healthcare Conference
July 28, 2022
Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2022 and Provide Corporate Update
- No Recent Filings Found.
